The joint-gut axis in inflammatory bowel diseases

Journal of Crohn's and Colitis

Volumn 4, Issue 3, 2010, Pages 257-268

  Brakenhoff, Lianne K P M ^a   van der Heijde, Désirée M ^a   Hommes, Daniel W ^a   Huizinga, Tom W J ^a   Fidder, Herma H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Arthralgia; Crohn's disease; Extraintestinal manifestations; Inflammatory bowel diseases; Spondyloarthropathies; Ulcerative colitis

Indexed keywords

ADALIMUMAB; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETANERCEPT; HLA B27 ANTIGEN; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE;

ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; BACKACHE; CLINICAL FEATURE; CLINICAL TRIAL; CROHN DISEASE; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG TOLERABILITY; ENTERITIS; ENTHESITIS; HUMAN; INTESTINE; LABORATORY TEST; LYMPHOCYTE; MORBIDITY; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REVIEW; SACROILIITIS; SPONDYLOARTHROPATHY; ULCERATIVE COLITIS;

EID: 77955279153     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2009.11.005     Document Type: Review

References (119)

1. Bernstein C.N., Blanchard J.F., Rawsthorne P., Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol Apr 2001, 96(4):1116-1122.
2. Greenstein A.J., Janowitz H.D., Sachar D.B. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) Sep 1976, 55(5):401-412.
3. Lakatos L., Pandur T., David G., Balogh Z., Kuronya P., Tollas A., et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol Oct 2003, 9(10):2300-2307.
4. Rankin G.B., Watts H.D., Melnyk C.S., Kelley M.L. National cooperative Crohn's disease study: extraintestinal manifestations and perianal complications. Gastroenterology Oct 1979, 77(4 Pt 2):914-920.
5. Veloso F.T., Carvalho J., Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol Jul 1996, 23(1):29-34.
6. Lanna C.C., Ferrari M.L., Rocha S.L., Nascimento E., de Carvalho M.A., da Cunha A.S. A cross-sectional study of 130 Brazilian patients with Crohn's disease and ulcerative colitis: analysis of articular and ophthalmologic manifestations. Clin Rheumatol Apr 2008, 27(4):503-509.
7. Mekhjian H.S., Switz D.M., Melnyk C.S., Rankin G.B., Brooks R.K. Clinical features and natural history of Crohn's disease. Gastroenterology Oct 1979, 77(4 Pt 2):898-906.
8. Orchard T.R., Wordsworth B.P., Jewell D.P. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut Mar 1998, 42(3):387-391.
9. Salvarani C., Vlachonikolis I.G., van der Heijde D.M., Fornaciari G., Macchioni P., Beltrami M., et al. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol Dec 2001, 36(12):1307-1313.
10. Dougados M., van der Linden S., Juhlin R., Huitfeldt B., Amor B., Calin A., et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum Oct 1991, 34(10):1218-1227.
11. de Vlam K., Mielants H., Cuvelier C., de Keyser F., Veys E.M., de Vos M. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol Dec 2000, 27(12):2860-2865.
12. Dekker-Saeys B.J., Meuwissen S.G., van den Berg-Loonen E.M., de Haas W.H., Agenant D., Tytgat G.N. Ankylosing spondylitis and inflammatory bowel disease. II. Prevalence of peripheral arthritis, sacroiliitis, and ankylosing spondylitis in patients suffering from inflammatory bowel disease. Ann Rheum Dis Feb 1978, 37(1):33-35.
13. Palm O., Moum B., Jahnsen J., Gran J.T. The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatology (Oxford) Nov 2001, 40(11):1256-1261.
14. Farmer R.G., Hawk W.A., Turnbull R.B. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology Apr 1975, 68(4 Pt 1):627-635.
15. Moeller J.L. Inflammatory bowel disease arthropathy. Curr Sports Med Rep Apr 2005, 4(2):105-107.
16. Palm O., Moum B., Ongre A., Gran J.T. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol Mar 2002, 29(3):511-515.
17. Ardizzone S., Puttini P.S., Cassinotti A., Porro G.B. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis Jul 2008, 40(Suppl 2):S253-S259.
18. Caprilli R., Gassull M.A., Escher J.C., Moser G., Munkholm P., Forbes A., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut Mar 2006, 55(Suppl 1):i36-i58.
19. Palm O., Bernklev T., Moum B., Gran J.T. Non-inflammatory joint pain in patients with inflammatory bowel disease is prevalent and has a significant impact on health related quality of life. J Rheumatol Sep 2005, 32(9):1755-1759.
20. Baeten D., de Keyser F., Mielants H., Veys E.M. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol Sep 2002, 16(4):537-549.
21. Peeters H., vanderCruyssen B., vander Cruyssen B., Mielants H., de Vlam K., Vermeire S., et al. Clinical and genetic factors associated with sacroiliitis in Crohn's disease. J Gastroenterol Hepatol Jan 2008, 23(1):132-137.
22. Queiro R., Maiz O., Intxausti J., de Dios, Belzunegui J., Gonzalez C., et al. Subclinical sacroiliitis in inflammatory bowel disease: a clinical and follow-up study. Clin Rheumatol 2000, 19(6):445-449.
23. Calin A., Porta J., Fries J.F., Schurman D.J. Clinical history as a screening test for ankylosing spondylitis. JAMA Jun 13 1977, 237(24):2613-2614.
24. Rudwaleit M., Metter A., Listing J., Sieper J., Braun J. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum Feb 2006, 54(2):569-578.
25. van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum Apr 1984, 27(4):361-368.
26. Kataria R.K., Brent L.H. Spondyloarthropathies. Am Fam Physician Jun 15 2004, 69(12):2853-2860.
27. Braun J., Baraliakos X., Golder W., Hermann K.G., Listing J., Brandt J., et al. Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional X-rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis Sep 2004, 63(9):1046-1055.
28. Sieper J., van der Heijde D.M., Landewé R., Brandt J., Burgos-Vagas R., et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis Jun 2009, 68(6):784-788.
29. Rudwaleit M., Landewé R., van der Heijde D., Listing J., Brandt J., Braun J., et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis Jun 2009, 68(6):770-776.
30. Rudwaleit M., van der Heijde D., Landewé R., Listing J., Akkoc N., Brandt J., et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis Jun 2009, 68(6):777-783.
31. de Vos M. Review article: joint involvement in inflammatory bowel disease. Aliment Pharmacol Ther Oct 2004, 20(Suppl 4):36-42.
32. Holden W., Orchard T., Wordsworth P. Enteropathic arthritis. Rheum Dis Clin North Am Aug 2003, 29(3):513-530. viii.
33. Steer S., Jones H., Hibbert J., Kondeatis E., Vaughan R., Sanderson J., et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. J Rheumatol Mar 2003, 30(3):518-522.
34. Koutroubakis I.E., Karmiris K., Bourikas L., Kouroumalis E.A., Drygiannakis I., Drygiannakis D. Antibodies against cyclic citrullinated peptide (CCP) in inflammatory bowel disease patients with or without arthritic manifestations. Inflamm Bowel Dis Apr 2007, 13(4):504-505.
35. Mielants H., Veys E.M., Goethals K., van der Straeten C., Ackerman C. Destructive lesions of small joints in seronegative spondylarthropathies: relation to gut inflammation. Clin Exp Rheumatol Jan 1990, 8(1):23-27.
36. Bourikas L.A., Papadakis K.A. Musculoskeletal manifestations of inflammatory bowel disease. Inflamm Bowel Dis Apr 30 2009, 15(12):1915-1924.
37. Olivieri I., D'Angelo S., Scarano E., Padula A. What is the primary lesion in SpA dactylitis?. Rheumatology (Oxford) May 2008, 47(5):561-562.
38. Braun J., Sieper J., Bollow M. Imaging of sacroiliitis. Clin Rheumatol 2000, 19(1):51-57.
39. Rudwaleit M., Khan M.A., Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?. Arthritis Rheum Apr 2005, 52(4):1000-1008.
40. Feldtkeller E., Khan M.A., van der Heijde D., van der Linden S., Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int Mar 2003, 23(2):61-66.
41. Song I.H., Carrasco-Fernandez J., Rudwaleit M., Sieper J. The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research. Ann Rheum Dis Nov 2008, 67(11):1535-1540.
42. Yu W., Feng F., Dion E., Yang H., Jiang M., Genant H.K. Comparison of radiography, computed tomography and magnetic resonance imaging in the detection of sacroiliitis accompanying ankylosing spondylitis. Skeletal Radiol Jun 1998, 27(6):311-320.
43. Blum U., Buitrago-Tellez C., Mundinger A., Krause T., Laubenberger J., Vaith P., et al. Magnetic resonance imaging (MRI) for detection of active sacroiliitis-a prospective study comparing conventional radiography, scintigraphy, and contrast enhanced MRI. J Rheumatol Dec 1996, 23(12):2107-2115.
44. Oostveen J., Prevo R., den Boer J., van de Laar M. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. J Rheumatol Sep 1999, 26(9):1953-1958.
45. Docherty P., Mitchell M.J., MacMillan L., Mosher D., Barnes D.C., Hanly J.G. Magnetic resonance imaging in the detection of sacroiliitis. J Rheumatol Mar 1992, 19(3):393-401.
46. Inanc N., Atagunduz P., Sen F., Biren T., Turoglu H.T., Direskeneli H. The investigation of sacroiliitis with different imaging techniques in spondyloarthropathies. Rheumatol Int Oct 2005, 25(8):591-594.
47. Puhakka K.B., Jurik A.G., Schiottz-Christensen B., Hansen G.V., Egund N., Christiansen J.V., et al. MRI abnormalities of sacroiliac joints in early spondylarthropathy: a 1-year follow-up study. Scand J Rheumatol 2004, 33(5):332-338.
48. Murphey M.D., Wetzel L.H., Bramble J.M., Levine E., Simpson K.M., Lindsley H.B. Sacroiliitis: MR imaging findings. Radiology Jul 1991, 180(1):239-244.
49. Rudwaleit M., Jurik A.G., Hermann K.G., Landewé R., van der Heijde D., Baraliakos X., et al. Defining active sacroiliitis on Magnetic Resonance Imaging (MRI) for classification of axial spondyloarthritis - a consensual approach by the ASAS/ OMERACT MRI Group. Ann Rheum Dis Oct 2009, 68(10):1520-1527.
50. Braun J., van der Heijde D. Imaging and scoring in ankylosing spondylitis. Best Pract Res Clin Rheumatol Sep 2002, 16(4):573-604.
51. Rothfuss K.S., Stange E.F., Herrlinger K.R. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol Aug 14 2006, 12(30):4819-4831.
52. Mielants H., Veys E.M., Cuvelier C., de Vos M., Goemaere S., de Clercq L., et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol Dec 1995, 22(12):2273-2278.
53. Mielants H., Veys E.M., Cuvelier C., de Vos M., Goemaere S., de Clercq L., et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol Dec 1995, 22(12):2279-2284.
54. de Vos M., Mielants H., Cuvelier C., Elewaut A., Veys E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology Jun 1996, 110(6):1696-1703.
55. Mielants H., Veys E.M., de Vos M., Cuvelier C., Goemaere S., de Clercq L., et al. The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol Dec 1995, 22(12):2266-2272.
56. Salmi M., Jalkanen S. Endothelial ligands and homing of mucosal leukocytes in extraintestinal manifestations of IBD. Inflamm Bowel Dis May 1998, 4(2):149-156.
57. Salmi M., Jalkanen S. Lymphocyte homing to the gut: attraction, adhesion, and commitment. Immunol Rev Aug 2005, 206:100-113.
58. Drayson M.T., Smith M.E., Ford W.L. The sequence of changes in blood flow and lymphocyte influx to stimulated rat lymph nodes. Immunology Sep 1981, 44(1):125-133.
59. Herman P.G., Yamamoto I., Mellins H.Z. Blood microcirculation in the lymph node during the primary immune response. J Exp Med Oct 1 1972, 136(4):697-714.
60. Cahill R.N., Frost H., Trnka Z. The effects of antigen on the migration of recirculating lymphocytes through single lymph nodes. J Exp Med Apr 1 1976, 143(4):870-888.
61. Nathan C. Points of control in inflammation. Nature Dec 19 2002, 420(6917):846-852.
62. Salmi M., Andrew D.P., Butcher E.C., Jalkanen S. Dual binding capacity of mucosal immunoblasts to mucosal and synovial endothelium in humans: dissection of the molecular mechanisms. J Exp Med Jan 1 1995, 181(1):137-149.
63. May E., Marker-Hermann E., Wittig B.M., Zeitz M., Meyer zum Buschenfelde K.H., Duchmann R. Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology Dec 2000, 119(6):1745-1755.
64. Salmi M., Rajala P., Jalkanen S. Homing of mucosal leukocytes to joints. Distinct endothelial ligands in synovium mediate leukocyte-subtype specific adhesion. J Clin Invest May 1 1997, 99(9):2165-2172.
65. Salmi M., Jalkanen S. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. J Immunol Apr 1 2001, 166(7):4650-4657.
66. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature May 31 2001, 411(6837):603-606.
67. Bouma G., Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol Jul 2003, 3(7):521-533.
68. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature May 31 2001, 411(6837):599-603.
69. Hampe J., Cuthbert A., Croucher P.J., Mirza M.M., Mascheretti S., Fisher S., et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet Jun 16 2001, 357(9272):1925-1928.
70. Carneiro L.A., Travassos L.H., Girardin S.E. Nod-like receptors in innate immunity and inflammatory diseases. Ann Med 2007, 39(8):581-593.
71. Bonen D.K., Ogura Y., Nicolae D.L., Inohara N., Saab L., Tanabe T., et al. Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology Jan 2003, 124(1):140-146.
72. Vignal C., Singer E., Peyrin-Biroulet L., Desreumaux P., Chamaillard M. How NOD2 mutations predispose to Crohn's disease?. Microbes Infect Apr 2007, 9(5):658-663.
73. Peeters H., vander Cruyssen B., Laukens D., Coucke P., Marichal D., van den Berghe M., et al. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. Ann Rheum Dis Sep 2004, 63(9):1131-1134.
74. Kim T.H., Rahman P., Jun J.B., Lee H.S., Park Y.W., Im H.J., et al. Analysis of CARD15 polymorphisms in Korean patients with ankylosing spondylitis reveals absence of common variants seen in western populations. J Rheumatol Oct 2004, 31(10):1959-1961.
75. van der Paardt M., Crusius J.B., de Koning M.H., Murillo L.S., van de Stadt R.J., Dijkmans B.A., et al. CARD15 gene mutations are not associated with ankylosing spondylitis. Genes Immun Jan 2003, 4(1):77-78.
76. Ferreiros-Vidal I., Amarelo J., Barros F., Carracedo A., Gomez-Reino J.J., Gonzalez A. Lack of association of ankylosing spondylitis with the most common NOD2 susceptibility alleles to Crohn's disease. J Rheumatol Jan 2003, 30(1):102-104.
77. D'Amato M. The Crohn's associated NOD2 3020InsC frameshift mutation does not confer susceptibility to ankylosing spondylitis. J Rheumatol Nov 2002, 29(11):2470-2471.
78. Crane A.M., Bradbury L., van Heel D.A., McGovern D.P., Brophy S., Rubin L., et al. Role of NOD2 variants in spondylarthritis. Arthritis Rheum Jun 2002, 46(6):1629-1633.
79. Laukens D., Peeters H., Marichal D., vander Cruyssen B., Mielants H., Elewaut D., et al. CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Ann Rheum Dis Jun 2005, 64(6):930-935.
80. Smale S., Natt R.S., Orchard T.R., Russell A.S., Bjarnason I. Inflammatory bowel disease and spondylarthropathy. Arthritis Rheum Dec 2001, 44(12):2728-2736.
81. Cuvelier C., Barbatis C., Mielants H., De Vos M., Roels H., Veys E. Histopathology of intestinal inflammation related to reactive arthritis. Gut Apr 1987, 28(4):394-401.
82. Hammer R.E., Maika S.D., Richardson J.A., Tang J.P., Taurog J.D. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell Nov 30 1990, 63(5):1099-1112.
83. Taurog J.D., Richardson J.A., Croft J.T., Simmons W.A., Zhou M., Fernandez-Sueiro J.L., et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med Dec 1 1994, 180(6):2359-2364.
84. Brown M.A., Pile K.D., Kennedy L.G., Calin A., Darke C., Bell J., et al. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis Apr 1996, 55(4):268-270.
85. Olivieri I., Salvarani C., Cantini F., Ciancio G., Padula A. Ankylosing spondylitis and undifferentiated spondyloarthropathies: a clinical review and description of a disease subset with older age at onset. Curr Opin Rheumatol Jul 2001, 13(4):280-284.
86. Hermann E., Yu K.H., Meyer zum Buschenfelde D.T., Fleischer B. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet Sep 11 1993, 342(8872):646-650.
87. Reveille J.D. Major histocompatibility genes and ankylosing spondylitis. Best Pract Res Clin Rheumatol Jun 2006, 20(3):601-609.
88. Baeten D., Demetter P., Cuvelier C.A., Kruithof E., van Damme N., de Vos M., et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol Mar 2002, 196(3):343-350.
89. Demetter P., de Vos M., van Huysse J.A., Baeten D., Ferdinande L., Peeters H., et al. Colon mucosa of patients both with spondyloarthritis and Crohn's disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis Feb 2005, 64(2):321-324.
90. Demetter P., Baeten D., de Keyser F., de Vos M., van Damme N., Verbruggen G., et al. Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex. Ann Rheum Dis Mar 2000, 59(3):211-216.
91. Karimi O., Pena A.S. Indications and challenges of probiotics, prebiotics, and synbiotics in the management of arthralgias and spondyloarthropathies in inflammatory bowel disease. J Clin Gastroenterol Sep 2008, 42(Suppl 3 Pt 1):S136-S141.
92. Elewaut D., De Keyser F., Cuvelier C., Lazarovits A.I., Mielants H., Verbruggen G., et al. Distinctive activated cellular subsets in colon from patients with Crohn's disease and ulcerative colitis. Scand J Gastroenterol Jul 1998, 33(7):743-748.
93. Singh S., Graff L.A., Bernstein C.N. Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD?. Am J Gastroenterol May 2009, 104(5):1298-1313.
94. Biancone L., Michetti P., Travis S., Escher J.C., Moser G., Forbes A., et al. European evidence-based consensus on the management of ulcerative colitis: special situations. J Crohn's Colitis Mar 2008, 2(1):63-92.
95. Kefalakes H., Stylianides T.J., Amanakis G., Kolios G. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?. Eur J Clin Pharmacol Oct 2009, 65(10):963-970.
96. Sandborn W.J., Stenson W.F., Brynskov J., Lorenz R.G., Steidle G.M., Robbins J.L., et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol Feb 2006, 4(2):203-211.
97. Reinisch W., Miehsler W., Dejaco C., Harrer M., Waldhoer T., Lichtenberger C., et al. An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment Pharmacol Ther Jun 1 2003, 17(11):1371-1380.
98. Mahadevan U., Loftus E.V., Tremaine W.J., Sandborn W.J. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol Apr 2002, 97(4):910-914.
99. El M.Y., Youssef S., Ahmed I., El G.M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol Feb 2006, 101(2):311-317.
100. Zochling J., van der Heijde D., Burgos-Vargas R., Collantes E., Davis J.C., Dijkmans B., et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis Apr 2006, 65(4):442-452.
101. Brandt J., Haibel H., Cornely D., Golder W., Gonzalez J., Reddig J., et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum Jun 2000, 43(6):1346-1352.
102. Kruithof E., van den Bosch F., Baeten D., Herssens A., de Keyser F., Mielants H., et al. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis Mar 2002, 61(3):207-212.
103. van den Bosch F., Kruithof E., Baeten D., Herssens A., de Keyser F., Mielants H., et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum Mar 2002, 46(3):755-765.
104. de Keyser F., Baeten D., van den Bosch F., Kruithof E., Verbruggen G., Mielants H., et al. Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis. Drugs 2004, 64(24):2793-2811.
105. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet Apr 6 2002, 359(9313):1187-1193.
106. van den Bosch F., Kruithof E., de Vos M., de Keyser F., Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet Nov 25 2000, 356(9244):1821-1822.
107. Ellman M.H., Hanauer S., Sitrin M., Cohen R. Crohn's disease arthritis treated with infliximab: an open trial in four patients. J Clin Rheumatol Apr 2001, 7(2):67-71.
108. Herfarth H., Obermeier F., Andus T., Rogler G., Nikolaus S., Kuehbacher T., et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol Oct 2002, 97(10):2688-2690.
109. Generini S., Giacomelli R., Fedi R., Fulminis A., Pignone A., Frieri G., et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis Dec 2004, 63(12):1664-1669.
110. Kaufman I., Caspi D., Yeshurun D., Dotan I., Yaron M., Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int Aug 2005, 25(6):406-410.
111. Rispo A., Scarpa R., Di G.E., Cozzolino A., Lembo G., Atteno M., et al. Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. Scand J Rheumatol Sep 2005, 34(5):387-391.
112. Kruithof E., De Rycke L., Roth J., Mielants H., van den Bosch F., de Keyser F., et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum Dec 2005, 52(12):3898-3909.
113. Marzo-Ortega H., McGonagle D., O'Connor P., Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum Sep 2001, 44(9):2112-2117.
114. Sandborn W.J., Hanauer S.B., Katz S., Safdi M., Wolf D.G., Baerg R.D., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology Nov 2001, 121(5):1088-1094.
115. Marzo-Ortega H., McGonagle D., O'Connor P., Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis Jan 2003, 62(1):74-76.
116. Davis J.C., Revicki D., van der Heijde D.M., Rentz A.M., Wong R.L., Kupper H., et al. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum Aug 15 2007, 57(6):1050-1057.
117. Revicki D.A., Luo M.P., Wordsworth P., Wong R.L., Chen N., Davis J.C. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). J Rheumatol Jul 2008, 35(7):1346-1353.
118. van der Heijde D.M., Revicki D.A., Gooch K.L., Wong R.L., Kupper H., Harnam N., et al. Physical function, disease activity, and health-related quality-of-life outcomes after 3years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther Aug 17 2009, 11(4):R124.
119. Plosker G.L., Lyseng-Williamson K.A. Adalimumab: in Crohn's disease. BioDrugs 2007, 21(2):125-132.